Cypress Bioscience of San Diego, California has aquired worldwide licensing rights for Alexza Pharmaceutical’s Staccato Nicotine inhaler for smoking cessation. Alexza will receive $5 million up front, with another $1 million due upon meeting preclinical and clinical milestones. Read the company’s press release.
Cypress also announced that it purchased rights to an intranasal carbetocin product for the treatment of autism from Marina Biotech. Marina, formerly MDRNA, formerly Nastech, has completed Phase I studies of the formulation. The deal may eventually be worth up to $28 million. Read the company’s press release.
